Nate Edwards of Arya Consulting moderates a discussion with Elisabeth Gardiner of Tevard Biosciences and Donny Xu of the RTW Institute about the regulatory and manufacturing hurdles facing rare disease drug developers.
|Articles|January 2, 2015
- Pharmaceutical Technology-01-02-2015
- Volume 39
- Issue 1
Ross Charging Hopper Increases Efficiency
Ross’ high-efficiency charging hopper for High Shear Mixers with Solids/Liquid Injection Manifold (SLIM) Technology is designed for high-speed powder injection into liquids and eliminates the need for eductors or pumps. The design improves the rate of feed delivery at a steady pace and prevents the bridging of bulk solids, which include: fumed silica, CMC, guar gum, carbon black, carrageenan, xanthan gum, talc, alginates, pectin, titanium dioxide, calcium carbonate, starch, clays, alumina, carbomers, sugar, salts, and dye powders.
The 30HP SLIM mixer is equipped with three level transmitters and a solenoid-operated multi-position modulating valve to maintain a liquid flow rate within 80% to 100% of the 500 gpm design flow rate. All contact parts are made of stainless steel 316 polished to 150-grit (32 Ra) finish.
Ross, Charles & Son Company
Article DetailsPharmaceutical Technology
Vol. No. 1
Page: 14
Articles in this issue
almost 12 years ago
Value-Based Healthcare in the: United Kingdomalmost 12 years ago
Mitigating Risk for Single-Use Assemblies in Sterile Fillingalmost 12 years ago
Building a Barrier in Solid-Dosage Drug Packagingalmost 12 years ago
Using Tocophersolan for Drug Deliveryalmost 12 years ago
Industry Expert Q&A with Fred Miesowiczalmost 12 years ago
Innovative Excipients in Solid-Dosage Manufacturingalmost 12 years ago
Great Expectations from New European Commissionalmost 12 years ago
Analyzing Protein Aggregation in Biopharmaceuticalsalmost 12 years ago
Standards Organizations Updatealmost 12 years ago
Politics and Patients to Shape Pharma in 2015Related to this article
FDA grants ravulizumab accelerated approval in IgA nephropathy after a 43.4% proteinuria cut, signaling new IV biologic demand for drug manufacturers.
Jane Zhang of ETCH Sourcing explains why geopolitics, transparency, and partnership now weigh as heavily as cost and quality when companies choose suppliers, in this episode of Ask the Expert, moderated by Susan J. Schniepp of Nelson Labs.
FDA approves GSK's bepirovirsen for chronic hepatitis B after a 19% functional cure rate, raising oligonucleotide scale-up stakes for manufacturers.
Ravi Kiran Kaja, PhD, USP, explains what harmonization of extractables and leachables standards looks like in practice.
Jaenisch, Muraru, and Pandey discuss new skills for QC and regulatory teams, plus patient trust, as new approach methodologies reshape pharma.
Nine duloxetine recalls since 2024 show why generic drug manufacturers need route-level nitrosamine risk assessment, not end-product testing alone.
OpenAI acquired Orchestra Bio to pair AI agents that track drug development timelines with its Rosalind life sciences tools, raising oversight questions for pharma teams.
Trending on Pharmaceutical Technology
1
OpenAI Bets on Accelerating Drug Development Timelines With Orchestra Bio
2
AAPS PharmSci 360 2026: System Suitability Standards in E&L Testing
3
FDA Approves Bepirovirsen: Why Oligonucleotide CDMOs Should Take Note
4
Nitrosamine Problems and Industry Solutions: PharmTech Explained
5